Trial reportAmerican journal of ophthalmology2016
Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial.
Trial report in American journal of ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Pooled it
- Intravitreal steroids for macular edema in diabetes.The Cochrane database of systematic reviews · 2020Pooled it
- Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study.American journal of ophthalmology · 2021Trial
- Study on the differential expression of disulfidptosis-related genes and their association with immune regulation in patients with diabetic retinopathy.Scientific reports · 2026Article
- Endovascular thrombectomy of acute ischemic stroke patients with systemic lupus erythematosus: two case reports.Future science OA · 2025Article
- Comparative Tear Fluid Proteomics to Explore Treatment Responsiveness in Diabetic Macular Edema: A Pilot Study.Journal of proteome research · 2025Article
- Microvascular Changes after Epiretinal Membrane Vitrectomy with Intraoperative Intravitreal Dexamethasone Implant: An OCT Angiography Analysis.Diagnostics (Basel, Switzerland) · 2024Article
- Intravitreal DEX Implant for the Treatment of Diabetic Macular Edema: A Review of National Consensus.Pharmaceutics · 2023Review
- Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study.Eye (London, England) · 2023Article
- Exploring the angiographic-biologic phenotype in the IMAGINE study: quantitative UWFA and cytokine expression.The British journal of ophthalmology · 2022Article
- Review
- Molecular investigation of candidate genes for pyroptosis-induced inflammation in diabetic retinopathy.Frontiers in endocrinology · 2022Article
- Long-Term Oral Administration of Salidroside Alleviates Diabetic Retinopathy in db/db Mice.Frontiers in endocrinology · 2022Article
- Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema.International journal of molecular sciences · 2021Review
- Effect of dexamethasone intravitreal implant for refractory and treatment-naive diabetic macular edema in Taiwanese patients.Journal of the Chinese Medical Association : JCMA · 2021Article
- Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema.Journal of ophthalmology · 2021Article
- Hepatocyte growth factor is upregulated in ischemic retina and contributes to retinal vascular leakage and neovascularization.FASEB bioAdvances · 2020Article
- Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.Expert opinion on investigational drugs · 2020Review
- Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients.BMC ophthalmology · 2020Article
- Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration.PloS one · 2020Article
Corrections and comments
- Commented on by
- Commented on byReply.2016
Authors and funding
21 authors.
Funding
Abstract
purposeThe Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial measured aqueous pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection of dexamethasone implant or vascular endothelial growth factor (VEGF)-neutralizing protein and correlated changes in levels with changes in excess foveal thickness (EFT) to identify potential PPFs contributing to DME.
designProspective, randomized crossover clinical trial.
methodsTwenty DME patients randomized to dexamethasone implant or VEGF-neutralizing protein had aqueous taps and spectral-domain optical coherence tomography (SDOCT) at baseline and every 4 weeks for 28 weeks. Aqueous levels of 55 vasoactive proteins were measured with protein array. Crossover at week 16 provided changes in protein levels after each intervention in all 20 patients.
resultsAfter dexamethasone implant there was significant correlation between changes in levels of 13 vasoactive proteins with changes in EFT, including 3 known PPFs: angiopoietin-2 (r = 0.40, P = .001), hepatocyte growth factor (HGF; r = 0.31, P = .02), and endocrine gland-VEGF (EG-VEGF, r = 0.43, P < .001). Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix metalloproteinase-9 correlated with edema reduction after injection of a VEGF-neutralizing protein as well as dexamethasone implant, suggesting their modulation is likely secondary to changes in edema rather than causative.
conclusionsCorrelation of edema reduction with reduction in the PPFs angiopoietin-2, HGF, and EG-VEGF provides potential insight into the multifactorial molecular mechanism by which dexamethasone implants reduce edema and suggest that additional study is needed to investigate the contributions of these 3 factors to chronic DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.